AAVantgarde Bio is advancing best-in-class AAV gene therapies aimed at treating severe inherited retinal diseases (IRDs) that currently have no approved therapies. Its lead candidate, AAVB-039, is being evaluated in the CELESTE study to address Stargardt disease caused by ABCA4 mutations, alongside the >100-patient STELLA natural history study. A second program, AAVB-081, is in a Phase 1/2 LUCE trial for retinitis pigmentosa secondary to Usher syndrome type 1B arising from MYO7A mutations. Led by CEO Dr. Natalia Misciattelli, the company plans to use newly secured capital to achieve clinical proof-of-concept for both programs. The pipeline positions AAVantgarde to enter mid-stage development in two large, unmet IRD markets. Financially, the company has just closed a substantial $141 million Series B round to fund these milestones, underscoring strong investor confidence in its platform. No revenue or patient adoption metrics have yet been disclosed, consistent with its clinical-stage status.

Total raised

$206M

Funding rounds

2

Latest round

Series B

Latest activity

Nov 2025